Drug shows promise in reducing heart damage in cancer patients undergoing certain chemotherapy.

A heart failure drug, sacubitril-valsartan, has shown potential in reducing heart damage in cancer patients receiving anthracycline chemotherapy. In a study of 114 high-risk patients, the drug was linked to a 77% lower risk of further heart damage compared to a placebo. The medication improved heart function, but more research is needed on diverse patient groups to confirm the findings.

November 18, 2024
5 Articles